OBJECTIVES:

• Determine the maximum tolerated dose (MTD) of temozolomide using an extended continuous schedule in combination with thalidomide in patients with advanced melanoma.
• Determine the response rate to this combination using an extended continuous schedule at the MTD in 30 patients who have advanced metastatic melanoma without brain metastases and in 15 patients who have metastatic melanoma in the brain.
• Further characterize the safety and toxicity of this combination in these patients.

OUTLINE: This is a dose escalation study of temozolomide (phase I) followed by a response rate determination study (phase II).

Patients receive oral temozolomide daily for 6 weeks followed by 2-4 weeks of rest. Patients receive oral thalidomide daily for the entire 8-10 week course. Treatment continues in the absence of unacceptable toxicity or disease progression.

Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive treatment with temozolomide and thalidomide at the recommended phase II dose.

PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for phase I and then an additional 45 patients (15 with CNS disease, 30 without CNS disease) will be accrued for phase II of this study within 18 months.

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic malignant melanoma that is considered unresectable

  • Stage III or IV ocular, mucosal, or cutaneous melanoma
• Measurable disease
• No CNS disease (phase I only)

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 70-100%

Life expectancy:

• Not specified

Hematopoietic:

• Absolute granulocyte count at least 1,500/mm^3
• Platelet count at least 150,000/mm^3

Hepatic:

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT/SGPT no greater than 3 times ULN
• Alkaline phosphatase no greater than 3 times ULN

Renal:

• Creatinine no greater than 1.5 times ULN

Cardiovascular:

• No history of active angina
• No myocardial infarction within past 6 months
• No history of significant ventricular arrhythmia requiring medication with antiarrhythmics

Other:

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 4 weeks before and after study
• No frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)
• No preexisting neurotoxicity grade 2 or greater
• No serious concurrent infections treated with antibiotics
• No nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study
• No psychiatric disorders that would preclude study compliance
• No other medical condition or reason that would preclude study

• No other malignancy within the past 2 years except:

  • Nonmelanoma skin cancer
  • Carcinoma in situ of the cervix
  • History of T1a or b prostate cancer detected incidentally at TURP and comprising less than 5% of resected tissue with PSA normal since TURP
• No AIDS related illness
• HIV negative

PRIOR CONCURRENT THERAPY:

• Recovered from prior therapy

Biologic therapy:

• At least 4 weeks since prior biologic therapy
• At least 4 weeks since prior immunotherapy
• No concurrent immunotherapy

Chemotherapy:

• No prior systemic chemotherapy for metastatic melanoma
• No other concurrent chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• At least 4 weeks since prior radiotherapy, interstitial brachytherapy, or radiosurgery
• At least 3 weeks since prior radiotherapy to the brain if brain metastases from melanoma
• Prior radiotherapy to only indicator lesion allowed provided recent evidence of disease progression at that site
• No concurrent radiotherapy

Surgery:

• At least 2 weeks since prior surgery requiring general anesthesia